Skip to main content

Table 1 Baseline characteristics of the study population

From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

  Total
(n = 363)
E19del
(n = 175)
L858R
(n = 154)
Uncommon
(n = 34)
p value
Age, mean ± SD 67.6 ± 11.0 66.5 ± 11.8 69.1 ± 9.9 66.1 ± 10.8 0.076
Sex, male 137 (37.7) 68 (38.9) 59 (38.3) 10 (29.4) 0.572
BMI, kg/m2 24.0 ± 3.5 24.2 ± 3.6 23.6 ± 3.3 25.5 ± 4.0 0.012
Smoking status      0.691
 Never smoker 258 (71.3) 123 (70.3) 109 (71.2) 26 (76.5)  
 Ex-smoker 76 (21.0) 36 (20.6) 35 (22.9) 5 (14.7)  
 Current smoker 28 (7.7) 16 (9.1) 9 (5.9) 3 (8.8)  
Stage      0.361
 Stage III 31 (8.5) 15 (8.6) 11 (7.1) 5 (14.7)  
  Stage IV 332 (91.5) 160 (91.4) 143 (92.9) 29 (85.3)  
Previous chemotherapy     0.442
 0 292 (80.4) 137 (78.3) 126 (81.8) 29 (85.3)  
 1 61 (16.8) 34 (19.4) 24 (15.6) 3 (8.8)  
 ≥2 10 (2.8) 4 (2.3) 4 (2.6) 2 (5.9)  
EGFR TKIs      0.422
 Afatinib 102 (28.1) 53 (30.3) 38 (24.7) 11 (32.4)  
 Erlotinib 139 (38.3) 69 (39.4) 61 (39.6) 9 (26.5)  
 Gefitinib 122 (33.6) 53 (30.3) 55 (35.7) 14 (41.2)  
  1. Data are shown as n (%) per each group, unless otherwise noted
  2. E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations, SD standard deviation, BMI body mass index, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor